Immfinity Biotechnologies

Immunity is complicated. Immfinity lets our partners see clearly. We use our patented T cell epitope sequencing (Tope-seq) system to discover T cell receptor antigens and decode reactivity. This means de-risking and accelerating early development in new T cell receptor based immunotherapies and vaccines to prevent catastrophic failures in the clinic while ensuring resources go towards advancing only the best medicines. Our technology is based on real cells. We do functional assays based on directly testing millions of T cell epitopes simultaneously. No guesswork. We use our direct, function-first approach to help partner organizations avoid dangerous off-target T cell reactivity and mine the natural richness of the T cell repertoire to find the next great immunotherapeutic. If you've ever found yourself wondering what your T cells are recognizing, contact partnering@immfinity.com or visit to find out how we can help.